Thermo Fisher Scientific and SHL Medical Partner to Deliver Integrated Drug-Device Solutions
Thermo Fisher Scientific Inc., the world leader in serving science, has announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery technologies, alongside a major expansion of sterile fill-finish and autoinjector assembly capabilities at its Ridgefield, New Jersey facility. These combined initiatives establish a fully integrated, U.S.-based offering that spans sterile manufacturing, device assembly, and commercial packaging for drug-device combination products, enabling pharmaceutical and biotechnology companies to streamline operations and accelerate time to market.
Growing Demand for Patient-Centric Injectable Therapies
The global healthcare landscape is witnessing rapid growth in demand for patient-centric, self-administered injectable therapies, particularly across therapeutic areas Drug-Device such as autoimmune diseases, inflammatory disorders, and other chronic conditions. Patients and healthcare providers increasingly prefer solutions that allow treatment outside clinical settings, improving convenience and adherence. To address this shift, Thermo Fisher Scientific is expanding its pre-filled syringe (PFS) fill-finish capabilities and device assembly operations at its Ridgefield site. This investment ensures that the company can meet rising demand while maintaining the highest standards of quality, safety, and efficiency in drug manufacturing and delivery systems.
Integrated End-to-End Manufacturing Approach
At the core of this collaboration is the integration of SHL Medical’s Molly® autoinjector platform with Thermo Fisher’s global sterile manufacturing network. This integration creates a seamless, end-to-end solution that spans from drug substance manufacturing to the final packaged device ready for commercial distribution. By combining expertise in sterile fill-finish processes with advanced drug delivery device technologies, the partnership enables customers to benefit from a unified Drug-Device development and manufacturing pathway. This approach reduces complexity, eliminates the need for multiple vendors, and enhances coordination across the product lifecycle, ultimately improving efficiency and speed.
Expansion of Ridgefield as a Strategic U.S. Hub
Thermo Fisher Scientific acquired the Ridgefield, New Jersey facility from Sanofi in September 2025 as part of its broader strategy to strengthen its manufacturing footprint in the United States. The site is being transformed into a premier North American hub dedicated to integrated Drug-Device sterile fill-finish operations, autoinjector final assembly, and packaging services. By expanding domestic production capacity, Thermo Fisher aims to support customers’ supply chains more effectively while enhancing resilience and reducing reliance on international manufacturing networks. This investment Drug-Device aligns with industry trends toward localization and supply chain optimization, particularly in the life sciences sector.
Enhancing Supply Chain Efficiency and Speed
“The collaboration with SHL Medical, a global leader in autoinjectors, and our expansion in Ridgefield are important steps in helping our customers meet growing demand,” said Michelle Logan, Vice President, Drug Product – Steriles, North America at Thermo Fisher Scientific. “By fully integrating fill-finish with device assembly, we can simplify supply chains, accelerate timelines, and ultimately Drug-Device support our customers in delivering critical therapies to patients more efficiently.” This integrated approach allows pharmaceutical companies to reduce operational complexity, improve coordination, and achieve faster product commercialization while maintaining compliance with regulatory standards.
Strategic Collaboration to Support Customers
Under the non-exclusive strategic collaboration, Thermo Drug-Device Fisher Scientific and SHL Medical will provide comprehensive support for the Molly® autoinjector platform at the Ridgefield site. This includes device final assembly, packaging, and distribution services, ensuring that customers receive a fully integrated solution. The partnership is designed to simplify the development and manufacturing process for pharmaceutical and biotechnology companies, providing a streamlined pathway from drug formulation to finished product. By aligning their capabilities, both companies aim to deliver a consistent, high-quality experience that supports innovation and scalability across the industry.
Combining Expertise for Advanced Drug Delivery
“This collaboration with Thermo Fisher represents a significant Drug-Device milestone for SHL Medical and for the customers we jointly serve,” said Markus Puusepp, Chief Growth Officer at SHL Medical. “By combining SHL Medical’s proven Molly® autoinjector platform and global device expertise with Thermo Fisher’s leading sterile fill-finish and commercial manufacturing capabilities, we are creating a powerful, integrated solution.” The partnership leverages SHL Medical’s expertise in designing and manufacturing advanced drug delivery systems with Thermo Fisher’s extensive experience in sterile production Drug-Device and pharmaceutical services. Together, they aim to accelerate the development and commercialization of innovative therapies while ensuring consistent product quality and performance.
Strengthening Global Manufacturing Network
The addition of autoinjector capabilities at Ridgefield complements Thermo Fisher Scientific’s extensive global network of sterile manufacturing facilities. Key locations include sites in Allentown, Pennsylvania; Horsham in the United Kingdom; and planned expansion in Greenville, North Carolina. Additional investments in facilities such as Ferentino, Italy, and expansion across the Asia-Pacific region further enhance the company’s ability to provide integrated, scalable solutions to customers worldwide. This global network ensures that Thermo Fisher can support projects at every stage, from early development through large-scale commercial production, while maintaining flexibility and responsiveness to customer needs.
Advancing Patient-Centric Innovation
The collaboration reflects a broader industry shift toward patient-centric innovation, where therapies are designed not only for efficacy but also for ease of use and accessibility. Autoinjectors like the Molly® platform play a crucial role in enabling patients to self-administer treatments safely and conveniently, reducing the burden on healthcare systems and improving patient outcomes. By integrating device technology with manufacturing processes, Thermo Fisher Scientific and SHL Medical are helping to advance this vision, ensuring that life-changing therapies are delivered in formats that meet the needs of modern patients.
About Thermo Fisher Scientific
Thermo Fisher Scientific is the world leader in serving science, with annual revenues exceeding $40 billion. The company’s mission is to enable its customers to make the world healthier, cleaner, and safer. Thermo Fisher supports a wide range of applications, from life sciences research and analytical testing to diagnostics and pharmaceutical manufacturing. Its portfolio includes industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Through its global presence and commitment to innovation, Thermo Fisher provides customers with advanced technologies, purchasing convenience, and comprehensive support across the life sciences ecosystem.The strategic collaboration between Thermo Fisher Scientific and SHL Medical, combined with the expansion of the Ridgefield facility, represents a significant advancement in the development and manufacturing of drug-device combination products. By offering a fully integrated, end-to-end solution that encompasses sterile fill-finish, device assembly, and packaging, the partnership addresses critical industry challenges related to complexity, efficiency, and scalability. As demand for patient-centric injectable therapies continues to grow, this collaboration positions both companies to play a leading role in delivering innovative, high-quality solutions that improve patient outcomes and accelerate the availability of life-changing treatments worldwide.
Source link:https://www.businesswire.com/
